Clinical Trial Update: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a MEK inhibitor (MEK162) in combination with idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with Inv
• Acute Promyelocytic Leukemia
• Erythroleukemia
• Monocytic Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)
• MEK162 (binimetinib)

Snippet

Sponsor: Bruno C. Medeiros | Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Status: TERMINATED